Pharmaceutical

ASCO 2024: Tagrisso approaches standard of Care status for NSCLC

At the ASCO annual meeting, Tagrisso showed an improvement in progression free survival compared to placebo.

Jun 4, 2024 - 04:00
ASCO 2024: Tagrisso approaches standard of Care status for NSCLC
At the ASCO annual meeting, Tagrisso showed an improvement in progression free survival compared to placebo.
Read the original article

Tags:

Previous Article

ASCO 2024: American Cancer Society and ASCO combine cancer resource websites

Next Article

Lilly strikes deal with QurAlis for preclinical ALS candidate

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

CSL sees highest patent filings and grants during Augus...

Dec 10, 2023

STAT+: Sanofi ends deal for a rare disease drug after FTC voices monopoly concerns

STAT+: Sanofi ends deal for a rare disease drug after F...

Dec 11, 2023

Who’s acquiring who? Virtual care M&A activity in the pharmaceutical industry increased by 100% in Q1 2023

Who’s acquiring who? Virtual care M&A activity in the p...

May 28, 2023